Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795410 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1797151 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1794388 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1797148 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL13403267 | 0.98 | CHRNB4 (0.49) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL31568823 | 0.95 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL13403254 | 0.95 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL5187982 | 0.95 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL3538856 | 0.95 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL3538855 | 0.95 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951821-B2 | Devoided of activity on the opiate or 5-HT3 receptors, exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2; 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2011-05-31 | — | — | US | disclosed |
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| EP-1527048-B1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SANOFI-AVENTIS (FR) | 2007-08-23 | — | — | US | disclosed |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2007-07-05 | — | — | US | disclosed |
| EP-1499589-B1 | DERIVATIVES OF N-PHENYL(PIPERIDIN-2-YL)METHYL BENZAMIDE, THE PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | EP | disclosed |
| US-7205319-B2 | exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 | SANOFI-AVENTIS (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-07-21 | — | — | US | disclosed |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SLC1A2, SLC1A1, SLC1A5 | CHRNB4 3163/4885CHRNA3 2646/4885OPRM1 1288/4885 |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | HDAC6, NAT1, ARG2 | CHRNB4 2960/4885CHRNA3 2216/4885OPRM1 175/4885 |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | NPR3, NR4A3, PRMT3 | CHRNB4 389/4885CHRNA3 185/4885OPRM1 66/4885 |
| US-20070155789-A1 | N-[PHENYL(PIPERIDIN-2-YL)METHYL]BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN THERAPY | HDAC6, NAT1, ARG2 | CHRNB4 2960/4885CHRNA3 2216/4885OPRM1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.